Crossmark Global Holdings Inc. Buys 1,973 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Posted by Brenda Bartman on May 12th, 2026

Crossmark Global Holdings Inc. grew its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 31.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,214 shares of the company’s stock after acquiring an additional 1,973 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in BeOne Medicines were worth $2,495,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fiera Capital Corp lifted its stake in shares of BeOne Medicines by 20.1% in the third quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock worth $8,557,000 after buying an additional 4,205 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BeOne Medicines by 1,019.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,816 shares of the company’s stock worth $14,587,000 after buying an additional 38,992 shares in the last quarter. Slow Capital Inc. lifted its stake in shares of BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after buying an additional 9,280 shares in the last quarter. AIA Group Ltd lifted its stake in shares of BeOne Medicines by 31.4% in the third quarter. AIA Group Ltd now owns 32,303 shares of the company’s stock worth $11,006,000 after buying an additional 7,716 shares in the last quarter. Finally, Generali Investments Management Co LLC bought a new position in shares of BeOne Medicines in the third quarter worth approximately $2,726,000. 48.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 341 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.62% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on ONC shares. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Barclays upped their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a research note on Thursday. Guggenheim upped their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $391.00.

Get Our Latest Stock Analysis on ONC

BeOne Medicines Stock Down 0.4%

ONC opened at $310.75 on Tuesday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a 50 day moving average price of $300.37 and a 200-day moving average price of $321.92. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $218.31 and a twelve month high of $385.22. The stock has a market capitalization of $34.10 billion, a price-to-earnings ratio of 69.52 and a beta of 0.50.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion during the quarter. Equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.3 earnings per share for the current year.

BeOne Medicines Profile

(Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report).

Institutional Ownership by Quarter for BeOne Medicines (NASDAQ:ONC)

Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.